A trial of masitinib and sunitinib for gastrointestinal stromal tumours that have got worse despite having imatinib

This trial is comparing 2 drugs called masitinib and sunitinib for a rare type of soft tissue sarcoma called gastrointestinal stromal tumour or GIST. The people taking part have a GIST that has spread to another part of their body or can’t be removed with surgery.

If a GIST can’t be removed with surgery, or has spread to another part of your body, you may have a drug called imatinib. It is a type of biological therapy called a tyrosine kinase inhibitor or TKI.

Imatinib stops signals that cancer cells use to divide and grow. But GISTs may get worse despite having imatinib. Researchers are looking for new treatments to help people in this situation.

In this trial they are looking at 2 other TKI drugs called sunitinib and masitinib. The aims of the trial are to compare the 2 drugs to

• See which is better for GISTs that have got worse despite having imatinib

• Learn more about the side effects